Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
Current Research in Tuberculosis
  Year: 2009 | Volume: 1 | Issue: 1 | Page No.: 9-14
DOI: 10.3923/crt.2009.9.14
Adjuvant Immunotherapy of Extensively Drug-Resistant Tuberculosis (XDR-TB) in Ukraine
Nathalia D. Prihoda, Olga V. Arjanova, Larisa V. Yurchenko, Nina I. Sokolenko, Lyudmila A. Vihrova, Volodymyr S. Pylypchuk, Valery M. Frolov and Galyna A. Kutsyna

Abstract:
Conventional TB chemotherapy success rates are very low in patients with Extensively Drug-Resistant Tuberculosis (XDR-TB). We treated twelve XDR-TB individuals, seven of which in addition to standard Anti-TB Therapy (ATT) received Immunoxel (Dzherelo), Svitanok and Lisorm over-the-counter herbal immunomodulators. All seven patients who received adjunct immunotherapy improved clinically and radiologically and were discharged after 3.7±0.8 months, with average/median time to mycobacterial clearance 28/25 days. None of five patients on TB drugs alone improved and one died. Patients on immune intervention gained 9.6 kg (p = 0.0001) while those on ATT lost 1.4 kg. The levels of total bilirubin decreased from 15.6 to 10.7 μmol L-1, similarly, the values of alanine transaminase (ALT) declined from abnormally high 42.6 IU L-1 to normal levels 22.9 IU L-1 (p = 0.23). Patients on ATT had unchanged levels of bilirubin, but their ALT declined from 29.6 to 12 IU L-1 (p = 0.02). The levels of hemoglobin rose from 104.1 to 118 g L-1 (p = 0.07) whereas leukocyte counts descended to normal levels from 8.9 to 7.3x109 cells L-1 (p = 0.003). Conversely, in patients on ATT leukocyte counts rose from 8.7 to 13.8x109 cells L-1 (p = 0.21), whereas hemoglobin declined to below normal levels from 116.4 to 96.6 g L-1 (p = 0.18). These results show that immune-modulating interventions can favorably influence the effect of TB drugs. The difference between two treatment outcomes was highly significant (Mantel Haenszel odds ratio = 11; p = 0.0009 at 95% CI). Thus, adjunct herbal immunotherapy is safe, shortens treatment duration and can overcome drug resistance even in patients with XDR-TB.
 [Fulltext PDF]   [Fulltext HTML]   [XML: Abstract + References]   [References]   [View Citation]  [Report Citation]
 RELATED ARTICLES:
  •    Mycobacterium tuberculosis Infection: A Data Based Review on Tuberculosis in Khuzestan, Iran
How to cite this article:

Nathalia D. Prihoda, Olga V. Arjanova, Larisa V. Yurchenko, Nina I. Sokolenko, Lyudmila A. Vihrova, Volodymyr S. Pylypchuk, Valery M. Frolov and Galyna A. Kutsyna, 2009. Adjuvant Immunotherapy of Extensively Drug-Resistant Tuberculosis (XDR-TB) in Ukraine. Current Research in Tuberculosis, 1: 9-14.

DOI: 10.3923/crt.2009.9.14

URL: https://scialert.net/abstract/?doi=crt.2009.9.14

COMMENTS
09 May, 2009
Ayea:
The only way to get rid of a temptation is to yield to it. classification health international organization world
 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 

Curve Bottom